Use “Specified Clinical Research” Data for Drug Approval: Regulatory Science Society
To read the full story
Related Article
- JPMA Official Renews Call for Use of “Specified Clinical Research” Data in Application Dossiers
December 7, 2018
- JPMA Official Hails MHLW Discussions on Use of “Specified Clinical Research” Data in Application Dossiers
September 10, 2018
- MHLW Discussing Use of Data from “Specified Clinical Research” in Application Dossiers, Will Issue Preliminary Conclusions by March
August 29, 2018
- Tap Data from “Specified Clinical Research” for Early Trial, Conditional Approval: JPMA Official
April 24, 2018
- “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
- MHLW to Mull Use of Data from “Specified Clinical Research” for Drug Review: Official
April 10, 2017
ORGANIZATION
- PhRMA Slams CEA Expansion, Warns It Undermines Japan Growth Strategy
November 17, 2026
- UCB Japan President Kikuchi to Take Helm of EFPIA Japan
November 13, 2026
- Japan Pharmacy Group Renews Call to Scrap Off-Year Drug Price Revisions
November 13, 2026
- JPMA to Draw Up 2027 Strategic Plan Based on Industry Vision
November 13, 2026
- JMA Renews Backing for Hanako Jimi in 2028 Upper House Race
November 11, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





